Clinical Trials Logo

Preeclampsia clinical trials

View clinical trials related to Preeclampsia.

Filter by:

NCT ID: NCT03188900 Completed - Preeclampsia Clinical Trials

Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia

APHERESE
Start date: June 12, 2017
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

NCT ID: NCT03171480 Completed - Preeclampsia Clinical Trials

Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia

NOPE
Start date: October 30, 2017
Phase: Phase 4
Study type: Interventional

A randomized controlled trial (RCT) of nitric-oxide donor (NOD) isosorbide mononitrate (IMN) versus placebo as an adjuvant to misoprostol/ intra-cervical Foley bulb for induction of labor to decrease rate of cesarean deliveries in pregnancies complicated by preeclampsia (≥24/0 weeks' gestation)

NCT ID: NCT03088228 Completed - Clinical trials for Periodontal Diseases

Maternal Periodontal Status and Cytokines in Preeclampsia

Start date: February 2, 2015
Phase: N/A
Study type: Observational [Patient Registry]

Background: The purpose of this study is to examine the relationship between maternal preeclampsia and periodontal parameters and the correlation of these two disorders with maternal gingival crevicular fluid levels (GCF) of interleukin (IL)-35, interleukin-37 and interleukin-6. The investigators also investigated their relation to the severity of preeclampsia. Methods: 82 preeclamptic women were recruited to the study (29 healthy pregnant women, 30 mild preeclamptic patient, 23 severe preeclamptic patient ). The clinical periodontal parameters and GCF samples were collected in the first day of puerperium.

NCT ID: NCT03067298 Completed - Preterm Birth Clinical Trials

Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening

PREDICTION2
Start date: October 2016
Phase:
Study type: Observational

Preterm birth (PTB), preeclampsia (PE), fetal growth restriction (FGR) and intra-uterine fetal death (IUFD) constitutes the main causes of perinatal morbidity and mortality and are called "Great Obstetrical Syndromes". Algorithms to predict those outcomes have been developed by combining maternal characteristics (history, age, BMI, blood pressure), biochemical (sFlt-1, β-hCG, PlGF, AFP) and sonographic (uterine artery Doppler, 3D of placenta, cervical length, nasal bone measurement, nuchal translucency) markers. Another prospective observational study ("PREDICTION study" NCT 02189148) is also ongoing, which aims to validate those algorithms at the first trimester of pregnancy. Recent data suggest that repeating the same measurements later in pregnancy could improve the detection rates, allowing closer monitoring of high-risk patients and potential therapeutics under investigation. The current study (PREDICTION2) is an ancillary study of PREDICTION and aims at validating the use of these markers in a combined iterative manner in the prediction of preeclampsia and other obstetrical outcomes.

NCT ID: NCT02879942 Completed - Preeclampsia Clinical Trials

First Trimester Placental Assessment in the Screening of Preeclampsia and Intrauterine Growth Restriction

Start date: August 2016
Phase:
Study type: Observational

Preeclampsia (PE) and intrauterine growth restriction (IUGR) are clinical manifestations of placental insufficiency. These complications affect 5-15% of pregnancies, and are responsible for up to 20% of preterm births. Women who develop PE during pregnancy also have an increased risk for cardiovascular events, both at short and long term. This justifies the need to improve diagnostic tools to identify patients at risk for these complications. PE and IUGR are multifactorial entities. Screening algorithms should thus include several parameters to achieve high detection rates. Research has mainly focused in the analysis of biophysical and biochemical parameters, and the study of the placenta itself has not been included in current diagnostic strategies. Investigators hypothesize that detection rates of preeclampsia and intrauterine growth restriction could be improved by the study of placental characteristics in the first trimester of pregnancy.

NCT ID: NCT02854501 Completed - Preeclampsia Clinical Trials

Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders

Start date: September 2015
Phase:
Study type: Observational

The current study included the singleton pregnancies (without history of previous risk factors), had their homocysteine measured as part of a serum-screening program in addition to uterine artery Doppler. Sensitivity, specificity, positive and negative predictive values, for development of preeclampsia and other adverse pregnancy outcomes were assessed as follows; (1) Homocysteine cutoff level at 6.3 µmol/l; (2) Bilateral notches on Doppler with a mean RI >0.5, all unilateral notches with a mean RI >0.6, in addition, absence of notches with a mean RI >0.7; (3) Doppler assessment combined with the homocysteine cutoff (6.3 µmol/l).

NCT ID: NCT02835339 Completed - Preeclampsia Clinical Trials

Magnesium Sulfate in Obese Preeclamptics

Start date: July 12, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn how medications participant will receive in the course of their delivery are metabolized (broken down by the body). The investigators hope to learn more about the way drugs are metabolized by pregnant women, and how those drugs are distributed in the blood and body compartments and cleared in the urine, and how maternal body weight affects the metabolism. With this information the investigators will be able to develop a treatment regimen considering factors in the body that affect magnesium levels so that the investigators can improve treatment of pregnant women. The goal of the study is to understand how different dosing of magnesium sulfate affects blood levels of the magnesium in larger women.

NCT ID: NCT02813551 Completed - Preeclampsia Clinical Trials

ToRsemide for pOstpartum HYpertension

TROPHY
Start date: August 2016
Phase: Phase 2
Study type: Interventional

Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the incidence of persistent postpartum hypertension in preeclamptic women.

NCT ID: NCT02808494 Completed - Preeclampsia Clinical Trials

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

Start date: March 2016
Phase:
Study type: Observational

Sample Collection Study

NCT ID: NCT02797249 Completed - Preeclampsia Clinical Trials

Low Dose Aspirin in the Prevention of Preeclampsia in China

APPEC
Start date: December 7, 2016
Phase: Phase 3
Study type: Interventional

Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin in Chinese pregnant women, starting between 12+ and 20 weeks of pregnancy, based on clinical characteristics aiming to reduce the incidence of preeclampsia.